← Back to Patent Explorer
US5739288A Expired / Lapsed US ⏱️ 0.0 years remaining

Fibrin sealant compositions

Assignee: VIVOLUTION AS
•
Filing: 1995-05-26
•
Granted: 1998-04-14
•
Expires: 2015-05-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to fibrin sealants. More specifically, the invention relates to the use of a fibrin sealant wherein a composition comprising fibrin monomer or a composition comprising noncrosslinked fibrin is utilized as a component of the fibrin sealant.

Inventors

  • 👤 Peter A. D. Edwardson
  • 👤 John E. Fairbrother
  • 👤 Ronald S. Gardner
  • 👤 Derek A. Hollingsbee
  • 👤 Stewart A. Cederholm-Williams

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 19:16
CPC Classifications
C; C12; C12N; C12N11/00; C12N11/02; C12N11/10; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/363; A61K38/43; A61K38/45; A61K38/46; A61K38/48; A61K38/482; A61K38/4833; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/32; A61L17/00; A61L17/005; A61L24/00; A61L24/001; A61L24/0015; A61L24/04; A61L24/10; A61L24/106; A61L27/00; A61L27/14; A61L27/22; A61L27/225; A61P; A61P7/00; A61P7/04; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/75; C12N11/06; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/254; A61L2300/40; A61L2300/404; A61L2300/406; A61L2300/416; A61L2300/418; A61L2300/45

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 34 words
A composition comprising fibrin monomer in a concentration of between 10 and 200 mg/ml of said composition and an adjuvant selected from the group consisting of antibiotics, anticancer agents and histamine H 2 -antagonists.
Claim 2
Dependent Claim 34 words
A composition comprising fibrin monomer in a concentration of between 10 and 200 mg/ml of said composition and an adjuvant selected from the group consisting of antibiotics, anticancer agents and histamine H 2 -antagonists.
Claim 3
Dependent Claim 14 words
The composition of claim 1 wherein said concentration is between 25 and 50 mg/ml.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2001-04-13 2001-10-13 2002-04-14 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2005-04-13 2005-10-13 2006-04-14 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2009-04-13 2009-10-13 2010-04-14 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag